



ACCADEMIA NAZIONALE DI MEDICINA

Sezione di Oncologia

[Meet the Professor]

## **22<sup>nd</sup> Meet The Professor Advanced International Breast Cancer Course (AIBCC)**

Padova, September 17-18, 2026

Sezione di Oncologia

**[Program]**

**Thursday, September 17**

10.30 Introduction to the Conference  
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

10.45 ESMO President Elect – Welcome Remark  
Giuseppe Curigliano

**SESSION I – HR+/HER2-**

Chairpersons: Giuseppe Curigliano, Valentina Guarneri, Jacek Jassem

11.00 Clinical and biological definition of early and late risk of relapse  
Carmine De Angelis

11.20 Navigating adjuvant ET options  
Stephen Johnston

11.40 Opportunities for radiation therapy de-escalation  
Philip Poortmans

12.00 Exploiting endocrine resistance in advanced disease  
Gaia Griguolo

12.20 Revisited metastatic algorithm  
Peter Fasching

12.40 Discussion

13.20 *Lunch*

**SESSION II – HER2+**

Chairpersons: Pierfranco Conte, Lucia Del Mastro, Hesham A.G. Elghazaly

14.20 Turning biological heterogeneity into clinical action  
Aleix Prat

14.40 Treatment escalation: neoadjuvant vs post-neoadjuvant strategies  
Sibylle Loibl

15.00 Redefining 1<sup>st</sup> line for advanced disease: induction CT vs ADC? Duration? Which maintenance?  
Sandra Swain

15.20 Discussion

**15.40 Clinical Multidisciplinary Shooting Session 1 – HR+/HER2- and HER2+**

Panelists: Pierfranco Conte, Carmine De Angelis, Lucia Del Mastro, Hesham A.G. Elghazaly, Peter Fasching, Gaia Griguolo, Valentina Guarneri, Jacek Jassem, Sibylle Loibl, Stephen Johnston, Philip Poortmans, Aleix Prat, Tanja Spanic, Sandra Swain  
Shooter: Michele Bottosso

17.00 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2026

Sezione di Oncologia

17.15 **Lecture of the Awardee**

18.00 Adjourn

**Friday, September 18**

**SESSION III– TNBC**

Chairpersons: Valentina Guarneri, Aleix Prat, Fabio Puglisi

9.00 Markers of sensitivity/resistance to immunotherapy  
Maria Vittoria Dieci

9.20 Balancing escalation and de-escalation in eTNBC  
Hope Rugo

9.40 1<sup>st</sup> line PD-L1+: ADC + ICI for all?  
Mario Giuliano

10.00 Discussion

10.20 *Coffee break*

**SESSION IV– Round table discussion: focus on young women**

Chairpersons: Sibylle Loibl, Fedro A. Peccatori

10.50 Fertility and pregnancy – Matteo Lambertini  
Hereditary syndromes - Banu Arun  
Surgical management - Eleftherios Mamounas

12.00 Discussion

12.30 *Lunch*

**SESSION V – HOT TOPICS**

Chairpersons: Bettina Borisch, Michelino De Laurentiis, Sandra Swain

13.30 Clinical implications of liquid biopsy: MRD, monitoring, guide for target treatment  
Luca Malorni

13.50 AI applied to histopathology  
Frederique Penault-Ilorca

14.10 Dealing with new patterns of toxicity  
Federica Miglietta

14.30 The right to be forgotten: Ending Discrimination Against Cancer Survivors  
Grazia Scocca

14.50 Discussion

Sezione di Oncologia

15.20 **Clinical Multidisciplinary Shooting Session 2 – TNBC and special situations**

Panelists: Banu Arum, Bettina Borisch, Michelino De Laurentis, Maria Vittoria Dieci, Mario Giuliano, Matteo Lambertini, Sibylle Loibl, Luca Malorni, Eleftherios Mamounas, Federica Miglietta, Fedro A. Peccatori, Frederique Penault-Ilorca, Aleix Prat, Fabio Puglisi, Hope Rugo, Sandra Swain  
Shooter: Davide Massa

16.40 Take home messages and adjourn

Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

**[Aims]**

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 22<sup>nd</sup> AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

**[Addressed to]**

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Pharmacists.

**[Directors]**

Pierfranco Conte  
Coordinator Molecular Tumor Board, Rete Oncologica Veneta, Padova (I)  
Scientific Director S. Camillo Hospital, IRCCS, Venezia (I)

Valentina Guarneri  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Sezione di Oncologia

Philip Poortmans  
Former president of ESTRO and of ECCO  
Department of Radiation Oncology  
Iridium Network  
University of Antwerp  
Wilrijk-Antwerp (B)

Aleix Prat  
Clínic Barcelona Comprehensive Cancer Center  
University of Barcelona  
Barcelona (ES)

**[Scientific Committee]**

Bettina Borisch  
Institute of Global Health  
University of Geneva

Maria Vittoria Dieci  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Hesham A.G. Elghazaly  
Department of Clinical Oncology and nuclear medicine  
University of Ainshams  
Cairo (EG)

Jacek Jassem  
Department of Oncology and Radiotherapy  
Medical University of Gdansk (PL)

Stephen Johnston  
NIHR Biomedical Research Centre for Cancer  
Royal Marsden NHS Foundation Trust & Institute of Cancer Research  
London (UK)

Sibylle Loibl  
German Breast Group  
University of Frankfurt (D)

Eleftherios Mamounas  
Comprehensive Breast Program  
MD Anderson Cancer Center Orlando  
Orlando (F)

Fedro A. Peccatori  
Department of Medical Oncology  
European Institute of Oncology (IEO)  
Milano (I)

Sezione di Oncologia

Sandra Swain M.  
Professor of Medicine, Associate Dean Research Development  
Georgetown University Medical Center  
Washington (USA)

**[Speakers & Chairpersons]**

Banu Arun  
Department of Breast Medical Oncology, Division of Cancer Medicine  
MD Anderson Cancer Center  
Houston (USA)

Michele Bottosso  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Giuseppe Curigliano  
Department of Oncology  
European Institute of Oncology  
University of Milano (I)

Carmine De Angelis  
Scuola Superiore Meridionale  
Clinical and Translational Oncology - CTO  
Napoli

Michelino De Laurentiis  
Breast Unit  
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"  
Napoli (I)

Lucia Del Mastro  
Division of Medical Oncology  
IRCCS Ospedale Policlinico San Martino  
Genova (I)

Peter Fasching  
University Hospital Erlangen and Comprehensive Cancer Center  
Erlangen (D)

Mario Giuliano  
U.O. Oncologia Medica  
Università degli Studi "Federico II"  
Napoli

Gaia Griguolo  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Sezione di Oncologia

Matteo Lambertini  
Breast Unit  
IRCCS Ospedale Policlinico San Martino  
Genova (I)

Luca Malorni  
Division of Oncology  
Azienda USL Toscana Centro Nuovo Ospedale di Prato Santo Stefano  
Prato (I)

Davide Massa  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Federica Miglietta  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padova (I)

Frederique Penault-Llorca  
Centre Jean Perrin, University  
Clermont Ferrand (F)

Fabio Puglisi  
Department of Medical Oncology  
Centro di riferimento Oncologico (CRO), IRCCS, Aviano (I)  
Department of Medicine, University of Udine (I)

Hope Rugo  
Breast Oncology Clinical Trials Program  
UCSF Carol Franc Buck Breast Care Center  
San Francisco (USA)

Grazia Scocca  
Institute for European Studies  
Bruxelles (B)

Tanja Spanic  
Europa Donna Slovenia  
The European Breast Cancer Coalition Europa Donna  
Ljubljana (SLO)

**[Meeting Venue]**

Palazzo della Salute  
Via San Francesco, 90  
Padova



ACCADEMIA NAZIONALE DI MEDICINA

Sezione di Oncologia

**[ECM]**

Based on the application regulations approved by the CNFC, the National Academy of Medicine (provider no. 31), credits will be awarded.

**[Organizer]**

ACCADEMIA NAZIONALE DI MEDICINA

Direttore Generale: Stefania Ledda

Via Martin Piaggio, 17/6

16122 Genova

**[Information and registration]**

<http://meettheprofessor.accmed.org>

Tel +39 51 6360080

Cell. 335 7111976

[info.bologna@accmed.org](mailto:info.bologna@accmed.org)